The inhibition of an inflammatory protein drastically reduces consequential damage following a stroke. This has now been demonstrated by scientists from the University of Würzburg. Their discovery could significantly improve the treatment provided to stroke patients.
Blood vessels that supply the brain with vital oxygen are suddenly blocked by blood clots; this causes nerve cells to die, and the sufferer develops symptoms that include paralysis and speech disorders: this is the typical scenario for a stroke.
At this point, rapid action is needed: The sooner the blood clots are dissolved with medication, the less severe the consequential damage is for the sufferer as a rule. Yet, often patients reach a life-saving hospital too late. This delay is also one reason why the risk of dying from a stroke in Germany is around ten times higher than the danger of being injured in a traffic accident.
Excess pressure inside the skull
However, this lack of oxygen inside the brain is only one issue among many that can occur with a stroke. One dreaded side effect, for example, are inflammatory processes in the brain and water retention in the nervous tissue, which is known as cerebral edema formation. Since the brain is surrounded by a rigid cranial bone, excess pressure builds up inside the skull, initially affecting healthy brain tissue at the same time.
“There are many facets to a stroke. It is this that makes it so difficult to treat; after all, most drugs can only target one key area,” says Professor Christoph Kleinschnitz, head of the Stroke Unit at the University of Würzburg’s Department of Neurology.
Publication in the “Annals of Neurology”
This shortage of effective medications might very soon be a thing of the past, hopes the neurologist. Kleinschnitz and his team have succeeded in inhibiting a specific inflammatory protein and, in so doing, noticeably reducing the consequences of a stroke.
They were supported in this by the Würzburg biomedical scientist Professor Bernhard Nieswandt and neurologists from the University of Münster. The researchers present the results of their work in the online issue of the “Annals of Neurology”, the official journal of the American Neurological Association.
“It has been known for quite some time that the inflammatory protein plasma kallikrein damages the nervous tissue in several ways after a stroke,” explains Kleinschnitz. For instance, this protein contributes to the creation of further blood clots in the brain. It also intensifies the inflammation as well as cerebral edema.
So, as a first step, the scientists worked with mice that lacked the gene for plasma kallikrein. These animals developed dramatically smaller strokes and revealed fewer neurological deficiencies. “This observation was very promising but it initially had no relevance to usage on patients. We therefore had to find a way of inhibiting plasma kallikrein pharmacologically as well,” explains Dr. Eva Göb, a research associate on Kleinschnitz’s team.
Antibody is effective even hours later
For this reason, the Würzburg researchers used an antibody that annuls the effect of plasma kallikrein in the blood of the mice. As they were able to show, this method also mitigated the consequences of a stroke dramatically. “What is interesting here is that the antibody itself was still effective when it was injected into the animals with a delay of three hours after the onset of the stroke. This means that the antibody could possibly be used on stroke patients who are late arriving at a hospital,” says Kleinschnitz. However, further studies and a safety test need to be conducted first before that point is reached.
The work in Würzburg Collaborative Research Center (SFB) 688 was funded by the German Research Foundation (DFG).
“Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation” Eva Göb, Stephan Reymann, Friederike Langhauser, Michael K. Schuhmann, Peter Kraft, Ina Thielmann, Kerstin Göbel, Marc Brede, György Homola, László Solymosi, Guido Stoll, Christian Geis, Sven G. Meuth, Bernhard Nieswandt, Christoph Kleinschnitz. Annals of Neurology. Published online on January 27, 2015. doi: 10.1002/ana.24380.
Prof. Dr. Christoph Kleinschnitz, Department of Neurology at the University of Würzburg, T +49 (0)931 201-23756, email@example.com
Gunnar Bartsch | Julius-Maximilians-Universität Würzburg
Further reports about: > American Neurological Association > Julius-Maximilians-Universität > Neurology > STROKE > animals > blood clots > brain tissue > clots > edema > inflammatory > inflammatory processes > nerve cells > nervous > nervous tissue > plasma kallikrein > pressure > sufferer > vital oxygen
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy